GlycoMimetics Incorporated: Clinical Trials

16 completed, 7 terminated. 18 Phase 1, 6 Phase 2, 3 Phase 3.

By phase and status

Phase	Trials	Status
Phase 1	18	Completed 13, Terminated 5
Phase 2	6	Completed 4, Terminated 2
Phase 3	3	Terminated 2, Completed 1

Follow GlycoMimetics Incorporated: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Uproleselan With Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for AML Uproleselan, Fludarabine, Clofarabine - Acute Myeloid Leukemia, Pediatric Cancer	Phase 1	Terminated	Malika Kapadia	1	2022-10-06	2024-08-19
Safety, Tolerability and Efficacy of Uproleselan (GMI-1271) in Patients With COVID-19 Pneumonia Uproleselan - COVID-19 Pneumonia	Phase 1 / Phase 2	Terminated	Lena Napolitano, MD	6	2021-11-12	2023-07-10
Uproleselan, Azacitidine, and Venetoclax for the Treatment of Treatment Naive Acute Myeloid Leukemia Azacitidine, Uproleselan, Venetoclax - Acute Myeloid Leukemia	Phase 1	Terminated	Brian Jonas	16	2021-07-02	2026-02-23
Uproleselan (GMI-1271) for GI Toxicity Prophylaxis During Melphalan-Conditioned Autologous Hematopoietic Cell Transplantation (Auto-HCT) for Multiple Myeloma (MM) Uproleselan, Placebo, Melphalan - Multiple Myeloma	Phase 2	Completed	Washington University School of Medicine	51	2021-05-05	2023-12-15
A Study to Determine Safety and Tolerability of GMI-1359 in Subjects With HR+ Metastatic Breast Cancer GMI-1359 - HR+ Metastatic Breast Cancer, Breast Cancer	Phase 1	Terminated	GlycoMimetics Incorporated	4	2019-11-21	2022-03-22
Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia Uproleselan, Placebo - Acute Myeloid Leukemia	Phase 3	Terminated	GlycoMimetics Incorporated	388	2018-10-15	2024-07-29
A Study in Healthy Volunteers to Investigate How Much Test Medicine [14C]-Uproleselan is Taken up by the Body When Administered Directly Into the Vein (IV) Uproleselan - Healthy Subjects	Phase 1	Completed	GlycoMimetics Incorporated	5	2018-08-14	2019-05-14
A Study to Evaluate the Effect of Age on the Pharmacokinetics, Safety and Tolerability of IV Rivipansel. Rivipansel - Healthy	Phase 1	Completed	GlycoMimetics Incorporated	16	2017-01-01	2020-06-18
A Study to Evaluate the Effect of IV Doses of Rivipansel in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function Rivipansel - Moderate Hepatic Impairment, Normal Hepatic Function	Phase 1	Completed	GlycoMimetics Incorporated	16	2016-09-01	2020-07-09
Placebo-Controlled Single Dose Study to Evaluate Safety and Pharmacokinetics of GMI-1359 in Healthy Volunteers GMI-1359, Placebo - Healthy	Phase 1	Completed	GlycoMimetics Incorporated	58	2016-08-01	2019-03-04
Study to Assess Safety, Tolerability, and Efficacy of GMI-1271 in Patients With Calf-level Deep Venous Thrombosis (DVT) GMI-1271, Enoxaparin Sodium (Lovenox®) - Deep Venous Thrombosis	Phase 1 / Phase 2	Terminated	GlycoMimetics Incorporated	2	2016-07-01	2019-06-14
A Study to Determine the Efficacy, Safety and Pharmacokinetics of GMI-1271 as Adjunct to Standard of Care for the Treatment of Multiple Myeloma GMI-1271 - Multiple Myeloma	Phase 1	Completed	GlycoMimetics Incorporated	10	2016-06-01	2019-07-10
A Study to Evaluate the Effect of IV Doses of Rivipansel on Subjects With Renal Impairment and in Healthy Subjects Rivipansel - Renal Impairment, Healthy	Phase 1	Completed	GlycoMimetics Incorporated	28	2016-06-01	2020-06-18
Safety of Rivipansel (GMI-1070) in the Treatment of One or More Vaso-Occlusive Crises in Hospitalized Subjects With Sickle Cell Disease Rivipansel - Sickle Cell Anemia, Sickle Cell Disease	Phase 3	Terminated	GlycoMimetics Incorporated	154	2015-12-16	2021-02-10
A Study to Evaluate the PK, Safety and Tolerability of GMI-1271 With and Without Filgrastim in Healthy Adult Subjects GMI-1271, Filgrastim, Placebo Injection - Healthy Volunteers	Phase 1	Completed	GlycoMimetics Incorporated	54	2015-11-01	2018-02-27
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Rivipansel With rHuPH20 in Healthy Subjects Rivipansel, Placebo - Healthy	Phase 1	Completed	GlycoMimetics Incorporated	27	2015-10-01	2020-06-18
Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subjects With Sickle Cell Disease Rivipansel, Placebo - Anemia, Sickle Cell	Phase 3	Completed	Biossil Inc.	345	2015-06-17	2025-03-11
Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML GMI-1271, Mitoxantrone, Etoposide - Leukemia, Myeloid, Acute	Phase 1 / Phase 2	Completed	GlycoMimetics Incorporated	91	2015-03-01	2019-05-17
Phase I Study to Assess Safety and Pharmacokinetics of GMI-1271 in Healthy Adult Subjects GMI-1271, Placebo, Enoxaparin Sodium (Lovenox®) - Healthy Volunteers	Phase 1	Completed	GlycoMimetics Incorporated	32	2014-10-01	2018-02-27
Placebo-controlled Single Dose Study to Evaluate Safety and Pharmacokinetics of GMI-1271 in Healthy Volunteers GMI-1271, Placebo - Healthy Adult Subjects	Phase 1	Completed	GlycoMimetics Incorporated	28	2014-06-01	2018-02-27

Showing 20 of 23. Sign in to see all of them.

Conditions studied

Anemia, Sickle Cell (4)  ·  Leukemia, Myeloid, Acute (4)  ·  Vaso-Occlusive Crises (3)  ·  Multiple Myeloma (2)  ·  Breast Neoplasms (1)  ·  Neoplasms (1)  ·  Renal Insufficiency (1)  ·  Venous Thrombosis (1)

Interventions

uproleselan (12)  ·  rivipansel (9)  ·  Enoxaparin (2)  ·  enoxaparin sodium (2)  ·  Azacitidine (1)  ·  Busulfan (1)  ·  Clofarabine (1)  ·  Cytarabine (1)  ·  Etoposide (1)  ·  Filgrastim (1)  ·  Idarubicin (1)  ·  Melphalan (1)  ·  Mitoxantrone (1)  ·  fludarabine (1)  ·  fludarabine phosphate (1)

Countries

United States (20)  ·  Canada (4)  ·  Ireland (3)  ·  United Kingdom (3)  ·  Australia (2)  ·  Belgium (1)  ·  Denmark (1)  ·  France (1)  ·  Germany (1)  ·  Italy (1)  ·  Netherlands (1)  ·  Spain (1)

Top investigators

Helen Thackray, MD (2)  ·  Laura Sterling, MD (2)  ·  Suman Sood, MD (2)  ·  Barbara Cook, MD (1)  ·  Brian A Jonas (1)  ·  Daniel DeAngelo, MD, PhD (1)  ·  Daniel J DeAngelo, MD, PhD (1)  ·  Dorothy A Sipkins, MD, PhD (1)  ·  Jeremy Force, DO (1)  ·  Keith Stockerl-Goldstein, M.D. (1)  ·  Lena Napolitano, MD (1)  ·  Malika Kapadia, MD (1)  ·  Marilyn J Telen, MD (1)  ·  Michael O'Dwyer, MD (1)

Results publications

PMID 32579796, PMID 35120836, PMID 35981565, PMID 22129980, PMID 24988449, PMID 25733584, PMID 34543383

NIH funding

2014 (1), P30CA093373 (1)